Publication:
Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry.

dc.contributor.authorFreitas-Ferraz, Afonso B
dc.contributor.authorLerakis, Stamatios
dc.contributor.authorBarbosa Ribeiro, Henrique
dc.contributor.authorGilard, Martine
dc.contributor.authorCavalcante, João L
dc.contributor.authorMakkar, Raj
dc.contributor.authorHerrmann, Howard C
dc.contributor.authorWindecker, Stephan
dc.contributor.authorEnriquez-Sarano, Maurice
dc.contributor.authorCheema, Asim N
dc.contributor.authorNombela-Franco, Luis
dc.contributor.authorAmat-Santos, Ignacio
dc.contributor.authorMuñoz-García, Antonio J
dc.contributor.authorGarcia Del Blanco, Bruno
dc.contributor.authorZajarias, Alan
dc.contributor.authorLisko, John C
dc.contributor.authorHayek, Salim
dc.contributor.authorBabaliaros, Vasilis
dc.contributor.authorLe Ven, Florent
dc.contributor.authorGleason, Thomas G
dc.contributor.authorChakravarty, Tarun
dc.contributor.authorSzeto, Wilson Y
dc.contributor.authorClavel, Marie-Annick
dc.contributor.authorde Agustin, Alberto
dc.contributor.authorSerra, Vicenç
dc.contributor.authorSchindler, John T
dc.contributor.authorDahou, Abdellaziz
dc.contributor.authorAnnabi, Mohamed-Salah
dc.contributor.authorPelletier-Beaumont, Emilie
dc.contributor.authorPibarot, Philippe
dc.contributor.authorRodés-Cabau, Josep
dc.date.accessioned2023-02-08T14:41:23Z
dc.date.available2023-02-08T14:41:23Z
dc.date.issued2020-02-12
dc.description.abstractThis study sought to determine the incidence, clinical impact, and changes over time of mitral regurgitation (MR) in patients with low-flow, low-gradient aortic stenosis (LFLG-AS) undergoing transcatheter aortic valve replacement (TAVR). Few data exist on the clinical impact and changes in severity over time of MR in patients with LFLG-AS undergoing TAVR. A total of 308 TAVR candidates with LFLG-AS were included. Patients were categorized according to MR severity at baseline, and presence of MR improvement at 12-month follow-up. Clinical outcomes were assessed at 1 and 12 months (+ echocardiography), and yearly thereafter. Baseline mild and moderate-to-severe MR were present in 118 (38.3%) and 115 (37.3%) patients, respectively. MR was of functional and mixed etiology in 77.2% and 22.7% of patients, respectively. A total of 131 patients (42.5%) died after a median follow-up of 2 (1 to 3) years. Baseline moderate-or-greater MR had no impact on mortality (hazard ratio [HR]: 1.34; 95% confidence interval [CI]: 0.72 to 2.48) or heart failure hospitalization (HR: 1.02; 95% CI: 0.49 to 2.10). At 1-year follow-up, MR improved in 44.3% of patients and remained unchanged/worsened in 55.7%. The lack of MR improvement was associated with a higher risk of all-cause and cardiac mortality (HR: 2.02; 95% CI: 1.29 to 3.17; HR: 3.03; 95% CI: 1.27 to 7.23, respectively), rehospitalization for cardiac causes (HR: 1.50; 95% CI: 1.04 to 2.15), and an increased overall-mortality/heart failure rehospitalization (HR: 1.94; 95% CI: 1.25 to 3.02). A higher baseline left ventricular end-diastolic diameter and a higher increase in left ventricular ejection fraction were found to be independent predictors of MR improvement at 1-year follow-up (odds ratio: 0.69; 95% CI: 0.51 to 0.94; and odds ratio: 0.81; 95% CI: 0.67 to 0.96, respectively). Most TAVR candidates with LFLG-AS had some degree of MR, of functional origin in most cases. MR improved in about one-half of patients, with larger left ventricular size and a higher increase in left ventricular ejection fraction post-TAVR determining MR improvement over time. The lack of MR improvement at 1 year was associated with poorer outcomes.
dc.identifier.doi10.1016/j.jcin.2019.11.042
dc.identifier.essn1876-7605
dc.identifier.pmid32061600
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.jcin.2019.11.042
dc.identifier.urihttp://hdl.handle.net/10668/15113
dc.issue.number5
dc.journal.titleJACC. Cardiovascular interventions
dc.journal.titleabbreviationJACC Cardiovasc Interv
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.page.number567-579
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectlow-flow low-gradient aortic stenosis
dc.subjectmitral regurgitation
dc.subjectreduced left ventricular ejection fraction
dc.subjecttranscatheter aortic valve replacement
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAortic Valve
dc.subject.meshAortic Valve Stenosis
dc.subject.meshDisease Progression
dc.subject.meshFemale
dc.subject.meshHeart Failure
dc.subject.meshHeart Valve Prosthesis
dc.subject.meshHemodynamics
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMitral Valve
dc.subject.meshMitral Valve Insufficiency
dc.subject.meshPatient Readmission
dc.subject.meshProspective Studies
dc.subject.meshRecovery of Function
dc.subject.meshRegistries
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Factors
dc.subject.meshSeverity of Illness Index
dc.subject.meshTime Factors
dc.subject.meshTranscatheter Aortic Valve Replacement
dc.subject.meshTreatment Outcome
dc.titleMitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVR: Insights From the TOPAS-TAVI Registry.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication

Files